查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2082543

數位療法市場：2026-2032年全球市場預測（依產品類型、治療領域、平台、通路類型、最終用戶和部署模式分類）

Digital Therapeutics Market by Product Type, Therapy Area, Platform, Channel Type, End User, Deployment Mode - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，數位療法市場將成長至 180.5 億美元，複合年成長率為 15.92%。

主要市場統計數據
基準年 2025 64.1億美元
預計年份：2026年 73.7億美元
預測年份 2032 180.5億美元
複合年成長率 (%) 15.92%

數位療法（DTx）是基於實證醫學的軟體介入措施，旨在預防、控制或治療疾病，通常單獨使用或與藥物、醫療設備和醫療專業人員的護理相結合。該領域正從與健康相關的應用程式轉向受監管的醫療軟體，這些軟體以隨機臨床試驗、真實世界數據、網路安全措施、互通性標準和保險報銷機制為支持。

由於醫療保健系統長期面臨壓力，例如慢性病流行、行為健康領域人員短缺、人口老化以及需要將醫療服務擴展到醫院和診所之外，對數位療法的需求正在進一步成長。一些已確認的政策趨勢，例如美國食品藥物管理局（FDA）對醫療設備軟體的監管、德國的DiGA計畫、英國的DTAC框架、法國針對數位醫療設備的PECAN早期准入計畫以及美國關於遠端醫療監測的法規，都顯示數位療法正成為互聯醫療基礎設施的正式組成部分。

數位療法領域的變革性變化

數位療法的格局正從面向消費者的實驗階段轉向醫療服務提供者、保險公司、雇主、製藥業相關人員和公共衛生系統等企業級應用。在將解決方案推廣至大眾之前，買家越來越重視臨床有效性、健康經濟學證據、工作流程整合、可用性測試、資料安全性和可衡量的結果。

人工智慧對數位療法的累積影響

人工智慧 (AI) 透過實現自適應介入、個人化指導、風險分層、自然語言互動以及自動升級至醫療團隊等功能，提升了數位療法的價值。 AI 可以幫助調整介入強度，使其與患者的行為、合併症、社會風險因素和反應模式相匹配，從而提高兩次就診之間治療的適宜性。

數位療法應用方面的關鍵區域見解

北美仍然是數位療法商業化的領先地區，這得益於先進的數位醫療基礎設施、保險公司試點計畫、FDA對處方箋數位療法的先例批准，以及雇主對針對慢性病和行為健康問題的可擴展解決方案的需求。美國是商業化的主導推動力，這得益於遠端醫療監測的報銷代碼和基於價值的醫療保健模式的普及。同時，加拿大也受益於公共衛生領域的數位化進步、省級虛擬醫療計劃以及人們對慢性病管理日益成長的興趣。

針對東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵群體特定見解

東協市場（包括新加坡、印尼、馬來西亞、泰國、越南和菲律賓）對行動優先的數位療法越來越有吸引力，這得益於智慧型手機普及率的提高、都市區醫療保健需求的成長以及公私合作的數位醫療舉措。支持糖尿病、心血管代謝疾病、心理健康、呼吸系統疾病和藥物依從性的解決方案在那些能夠與當地報銷體系、語言障礙、臨床工作流程和資料居住要求相容的地區得到了最廣泛的應用。

各國對數位療法發展的洞察

美國憑藉其經FDA批准的軟體醫療核准途徑、用於遠端醫療監測的CPT編碼、已建立的數位醫療採購管道，以及雇主和保險公司對以結果為導向的醫療服務的關注，引領著數位療法（DTx）的商業化進程。加拿大則透過省級系統和國家數位醫療合作項目，推動虛擬醫療和慢性病管理的發展。同時，墨西哥和巴西則面臨著人口眾多、慢性病護理需求不斷成長以及私營部門對可擴展數位醫療服務日益成長的需求等挑戰。

為數位療法行業的領導者提供的實用建議

產業領導者應優先考慮已通過臨床驗證的應用案例，這些案例需能證明數位療法在糖尿病、高血壓、失眠、物質使用障礙、肌肉骨骼疾病、呼吸系統疾病、肥胖症、心血管風險管理和行為健康等領域具有可衡量的療效。證據策略應結合隨機試驗、真實世界數據、病患檢驗結局、衛生經濟學、用藥依從性指標、安全性監測和次組分析，以支持報銷和採購。

數字療法分析的調查方法

一套穩健的數位療法調查方法需要對監管文件、同行評審的臨床證據、保險公司政策、報銷代碼、臨床實踐指南、公共衛生資料集、採購活動、專利申請、產品註冊資訊以及專家訪談進行多方面的交叉引用。市場評估應明確區分健康應用程式和經臨床檢驗的數位療法、醫療設備軟體、遠端監測、互聯疾病管理以及數位醫療導航平台，以避免類別混淆。

結論：數位療法是醫療保健領域的核心成長市場

數位療法正逐漸成為現代醫療保健的重要組成部分，它透過臨床指導的軟體干預，將患者、臨床醫生、保險公司和生命科學相關人員聯繫起來。下一階段的市場發展將不再取決於應用程式的下載量，而是取決於實證醫學、報銷機制、整合性、網路安全、監管合規性和永續的健康結果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 數位療法市場：依產品類型分類

  • 無需處方箋/非處方（OTC）數位療法
  • 數位療法（PDTx）需要處方箋

第8章：數位療法市場：依治療領域分類

  • 糖尿病管理
  • 神經病變
    • 憂鬱症
    • 焦慮症
    • 思覺失調症
    • 癲癇
    • 多發性硬化症
  • 肥胖和體重管理
  • 慢性呼吸系統疾病
  • 心血管疾病
  • 心理和行為健康
  • 肌肉骨骼疾病/疼痛管理
  • 癌症支持護理
  • 消化系統疾病
  • 禁止抽煙
  • 女性健康
  • 復健及物理治療
  • 物質使用障礙
  • 睡眠障礙

第9章 數位療法市場：依平台分類

  • 基於智慧型手機的應用程式
  • DTx與穿戴式裝置整合
  • 利用人工智慧/機器學習的數位療法
  • 基於虛擬實境（VR）的數位化治療
  • 數位監控和回饋系統
  • 基於網路/跨平台的療法

第10章 數位療法市場：以通路類型分類

  • 病人/直接面對消費者 (D2C)
  • 醫療服務提供者（醫院和診所）
  • 雇主/公司健康計劃
  • 與製藥公司合作
  • 政府和公共衛生系統

第11章 數字療法市場：以最終用戶分類

  • 病人
  • 醫療服務提供方
  • 雇主和企業健康
  • 看護者及復健中心

第12章 數位療法市場：依部署模式分類

  • 基於雲端的
  • 現場
  • 混合實現

第13章 數字療法市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 數位療法市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 數位療法市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • 2morrow Inc.
  • Abbott Laboratories
  • AptarGroup, Inc.
  • Big Health, Inc.
  • Biofourmis Inc.
  • Canary Health Technologies Inc.
  • Click Therapeutics, Inc.
  • CogniFit Inc.
  • Cognoa, Inc.
  • CureApp, Inc.
  • DarioHealth Corp.
  • F. Hoffmann-La Roche Ltd
  • Fitterfly Healthtech Private Limited by PB Healthcare Services Pvt. Ltd.
  • GAIA AG
  • Glooko, Inc.
  • Grunenthal GmbH
  • H2O Therapeutics Co.
  • Headspace Inc.
  • Hinge Health, Inc.
  • Hyfe, Inc.
  • Kaia Health Software Inc.
  • Lark Technologies, Inc.
  • LifeScan, Inc.
  • Lumanity Inc.
  • Lumos Labs
  • MedRhythms
  • Noom, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Omada Health, Inc.
  • Otsuka Holdings Co., Ltd.
  • ResMed, Inc.
  • SilverCloud by American Well Corporation
  • Teladoc Health, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Vida Health, Inc.
  • Virtual Therapeutics Corp.
  • Welldoc, Inc.
Product Code: MRR-431752EA4722

The Digital Therapeutics Market is projected to grow by USD 18.05 billion at a CAGR of 15.92% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.41 billion
Estimated Year [2026] USD 7.37 billion
Forecast Year [2032] USD 18.05 billion
CAGR (%) 15.92%

Digital therapeutics (DTx) are evidence-based software interventions designed to prevent, manage, or treat disease, often used independently or alongside medication, devices, and clinician-led care. The category is moving from wellness-adjacent apps toward regulated medical software supported by randomized clinical trials, real-world evidence, cybersecurity controls, interoperability standards, and reimbursement pathways.

Demand is being reinforced by durable health system pressures: chronic disease prevalence, behavioral health shortages, aging populations, and the need to extend care beyond hospitals and clinics. Verified policy signals, including FDA oversight of software as a medical device, Germany's DiGA pathway, the U.K.'s DTAC framework, France's PECAN early access pathway for digital medical devices, and U.S. remote therapeutic monitoring codes, show that digital therapeutics are becoming a formal part of connected care infrastructure.

Transformative Shifts in the Digital Therapeutics Landscape

The digital therapeutics landscape is shifting from direct-to-consumer experimentation to enterprise adoption by providers, payers, employers, pharmaceutical stakeholders, and public health systems. Buyers increasingly require clinical validation, health economic evidence, workflow integration, usability testing, data security, and measurable outcomes before scaling solutions across populations.

A second shift is the convergence of DTx with telehealth, remote patient monitoring, electronic health records, pharmacy services, and value-based care contracts. This integration is changing the competitive benchmark: successful platforms must not only engage patients, but also deliver longitudinal data, clinician decision support, adherence insights, and compliance with privacy, accessibility, and medical device regulations.

Cumulative Impact of Artificial Intelligence on Digital Therapeutics

Artificial intelligence is amplifying the value of digital therapeutics by enabling adaptive interventions, personalized coaching, risk stratification, natural-language engagement, and automated escalation to care teams. AI can help match intervention intensity to patient behavior, comorbidities, social risk factors, and response patterns, improving the relevance of therapy between clinical visits.

The cumulative impact is also increasing regulatory and governance expectations. Industry leaders must validate AI models across diverse populations, monitor algorithm drift, document clinical safety, protect health data, and maintain explainability where outputs affect treatment. Responsible AI is becoming a competitive differentiator as payers, providers, and regulators demand evidence that digital therapeutics are safe, equitable, clinically meaningful, and auditable over time.

Key Regional Insights for Digital Therapeutics Adoption

North America remains a leading region for digital therapeutics commercialization due to advanced digital health infrastructure, payer experimentation, FDA precedent for prescription digital therapeutics, and employer demand for scalable chronic and behavioral health solutions. The United States is the primary commercialization engine, supported by remote therapeutic monitoring reimbursement codes and value-based care adoption, while Canada benefits from strong public health digitization, provincial virtual care initiatives, and growing attention to chronic disease management.

Europe is shaped by structured assessment and reimbursement models, particularly Germany's DiGA program, France's digital medical device reimbursement initiatives, the U.K.'s DTAC assessment framework, and broader EU emphasis on GDPR, medical device regulation, interoperability, and evidence-based software. Asia-Pacific is expanding as China, Japan, India, South Korea, and Australia invest in telehealth, mobile-first care, digital hospitals, and aging-population management. Latin America shows rising demand in diabetes, cardiovascular risk, mental health, and access-to-care use cases, with Brazil and Mexico acting as important adoption centers. The Middle East is accelerating through national digital health strategies in Gulf markets, where prevention, chronic care, and smart hospital programs are policy priorities. Africa remains earlier-stage but strategically important, with mobile health adoption, primary care access gaps, expanding broadband initiatives, and donor-supported digital health infrastructure creating long-term DTx opportunities.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are attractive for mobile-first digital therapeutics because smartphone penetration, urban healthcare demand, and public-private digital health initiatives are increasing across Singapore, Indonesia, Malaysia, Thailand, Vietnam, and the Philippines. Adoption is strongest where solutions support diabetes, cardiometabolic disease, mental health, respiratory care, and medication adherence while fitting local reimbursement, language, clinical workflow, and data residency requirements.

The European Union is advancing a rules-based DTx environment through GDPR, medical device regulation, health data space initiatives, cross-border interoperability priorities, and national reimbursement experiments. GCC countries are investing in digital health as part of economic diversification, preventive care strategies, and health system modernization, creating favorable conditions for digitally enabled chronic disease and behavioral health programs. BRICS markets represent scale, chronic disease burden, and cost-sensitive innovation potential, although regulatory heterogeneity, reimbursement fragmentation, and access disparities remain significant. G7 markets provide the deepest evidence, reimbursement, procurement, and clinical integration opportunities, while NATO countries overlap substantially with high-income digital health systems prioritizing cybersecurity, resilience, continuity of care, and trusted health data exchange.

Key Country Insights for Digital Therapeutics Growth

The United States leads in DTx commercialization, supported by FDA-recognized pathways for software-based medical interventions, CPT codes for remote therapeutic monitoring, established digital health procurement channels, and employer and payer interest in outcomes-based care. Canada is advancing virtual care and chronic disease management through provincial systems and national digital health collaboration, while Mexico and Brazil offer large populations, rising chronic disease needs, and growing private-sector demand for scalable digital health access.

In Europe, the United Kingdom's NHS assessment frameworks, Germany's DiGA reimbursement pathway, and France's digital medical device reimbursement initiatives make these markets influential for evidence standards and procurement expectations. Italy and Spain are strengthening telehealth, electronic health records, and chronic care modernization, while Russia remains complex due to geopolitical, reimbursement, and procurement constraints. In Asia-Pacific, China offers scale and policy-driven digital health expansion, India provides mobile-first demand and substantial chronic disease needs, Japan prioritizes aging-related care, regulated quality, and clinical safety, Australia supports remote care across dispersed populations, and South Korea combines strong connectivity with advanced digital hospital ecosystems and government interest in smart healthcare.

Actionable Recommendations for Digital Therapeutics Leaders

Industry leaders should prioritize clinically validated use cases where digital therapeutics can demonstrate measurable outcomes, such as diabetes, hypertension, insomnia, substance use disorder, musculoskeletal care, respiratory disease, obesity, cardiovascular risk management, and behavioral health. Evidence strategies should combine randomized trials, real-world evidence, patient-reported outcomes, health economics, adherence metrics, safety monitoring, and subgroup analyses to support reimbursement and procurement.

Companies should also design for integration from the start. Interoperability with EHRs, remote monitoring devices, pharmacy systems, care management platforms, and clinician workflows improves adoption and reduces abandonment. Leaders should invest in privacy-by-design, cybersecurity, health equity testing, AI governance, accessibility, localization, and payer-aligned value propositions that translate engagement into reduced utilization, improved adherence, better quality measures, and sustained patient outcomes.

Research Methodology for Digital Therapeutics Analysis

A robust digital therapeutics research methodology should triangulate regulatory documents, peer-reviewed clinical evidence, payer policies, reimbursement codes, clinical practice guidelines, public health datasets, procurement activity, patent filings, product registries, and expert interviews. Market assessment should distinguish wellness apps from clinically validated DTx, software as a medical device, remote monitoring, connected disease management, and digital care navigation platforms to avoid category inflation.

The methodology should evaluate adoption by indication, care setting, business model, regulatory classification, evidence maturity, prescribing pathway, reimbursement readiness, and integration depth. Regional analysis should incorporate healthcare financing, data protection laws, physician adoption, smartphone access, digital literacy, language localization, procurement models, and health system priorities. AI-related analysis should review validation protocols, bias mitigation, post-market surveillance, model governance, explainability, algorithm change control, and clinical safety documentation.

Conclusion: Digital Therapeutics as a Core Healthcare Growth Market

Digital therapeutics are becoming a strategic layer of modern healthcare, connecting patients, clinicians, payers, and life sciences stakeholders through clinically guided software interventions. The market's next phase will be defined less by app downloads and more by evidence, reimbursement, integration, cybersecurity, regulatory alignment, and sustained health outcomes.

Organizations that combine medical rigor with user-centered design, responsible AI, secure data practices, interoperability, and scalable partnerships will be best positioned to lead. As healthcare systems seek accessible, cost-effective, and personalized care models, digital therapeutics are set to play an expanding role in chronic disease management, behavioral health, preventive care, and digitally enabled population health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Digital Therapeutics Market, by Product Type

  • 7.1. Non-Prescription / Over-the-Counter (OTC) Digital Therapeutics
  • 7.2. Prescription Digital Therapeutics (PDTx)

8. Digital Therapeutics Market, by Therapy Area

  • 8.1. Diabetes Management
  • 8.2. Neurological Disorders
    • 8.2.1. Depression
    • 8.2.2. Anxiety Disorders
    • 8.2.3. Schizophrenia
    • 8.2.4. Epilepsy
    • 8.2.5. Multiple Sclerosis
  • 8.3. Obesity & Weight Management
  • 8.4. Chronic Respiratory Diseases
  • 8.5. Cardiovascular Diseases
  • 8.6. Mental & Behavioral Health
  • 8.7. Musculoskeletal Disorders / Pain Management
  • 8.8. Oncology Support Care
  • 8.9. Gastrointestinal Disorders
  • 8.10. Smoking Cessation
  • 8.11. Women's Health
  • 8.12. Rehabilitation & Physical Therapy
  • 8.13. Substance Use Disorders
  • 8.14. Sleep Disorders

9. Digital Therapeutics Market, by Platform

  • 9.1. Smartphone-Based Applications
  • 9.2. Wearable Device-Integrated DTx
  • 9.3. AI/ML-Based Digital Therapies
  • 9.4. Virtual Reality (VR)-Based DTx
  • 9.5. Digital Monitoring + Feedback Systems
  • 9.6. Web-Based / Cross-Platform Therapeutics

10. Digital Therapeutics Market, by Channel Type

  • 10.1. Patients / Direct-to-Consumer (D2C)
  • 10.2. Healthcare Providers (Hospitals & Clinics)
  • 10.3. Employers / Corporate Wellness Programs
  • 10.4. Pharmaceutical Partnerships
  • 10.5. Government & Public Health Systems

11. Digital Therapeutics Market, by End User

  • 11.1. Patients
  • 11.2. Healthcare Providers
  • 11.3. Employers & Corporate Wellness
  • 11.4. Caregivers & Rehabilitation Centers

12. Digital Therapeutics Market, by Deployment Mode

  • 12.1. Cloud-Based
  • 12.2. On-Premise
  • 12.3. Hybrid Deployment

13. Digital Therapeutics Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Digital Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Digital Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. 2morrow Inc.
  • 17.2. Abbott Laboratories
  • 17.3. AptarGroup, Inc.
  • 17.4. Big Health, Inc.
  • 17.5. Biofourmis Inc.
  • 17.6. Canary Health Technologies Inc.
  • 17.7. Click Therapeutics, Inc.
  • 17.8. CogniFit Inc.
  • 17.9. Cognoa, Inc.
  • 17.10. CureApp, Inc.
  • 17.11. DarioHealth Corp.
  • 17.12. F. Hoffmann-La Roche Ltd
  • 17.13. Fitterfly Healthtech Private Limited by PB Healthcare Services Pvt. Ltd.
  • 17.14. GAIA AG
  • 17.15. Glooko, Inc.
  • 17.16. Grunenthal GmbH
  • 17.17. H2O Therapeutics Co.
  • 17.18. Headspace Inc.
  • 17.19. Hinge Health, Inc.
  • 17.20. Hyfe, Inc.
  • 17.21. Kaia Health Software Inc.
  • 17.22. Lark Technologies, Inc.
  • 17.23. LifeScan, Inc.
  • 17.24. Lumanity Inc.
  • 17.25. Lumos Labs
  • 17.26. MedRhythms
  • 17.27. Noom, Inc.
  • 17.28. Novartis AG
  • 17.29. Novo Nordisk A/S
  • 17.30. Omada Health, Inc.
  • 17.31. Otsuka Holdings Co., Ltd.
  • 17.32. ResMed, Inc.
  • 17.33. SilverCloud by American Well Corporation
  • 17.34. Teladoc Health, Inc.
  • 17.35. Teva Pharmaceutical Industries Ltd.
  • 17.36. Vida Health, Inc.
  • 17.37. Virtual Therapeutics Corp.
  • 17.38. Welldoc, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIGITAL THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL DIGITAL THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL DIGITAL THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL DIGITAL THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIGITAL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL DIGITAL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NON-PRESCRIPTION / OVER-THE-COUNTER (OTC) DIGITAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NON-PRESCRIPTION / OVER-THE-COUNTER (OTC) DIGITAL THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON-PRESCRIPTION / OVER-THE-COUNTER (OTC) DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (PDTX) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (PDTX) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (PDTX) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DIABETES MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIABETES MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DIABETES MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DEPRESSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DEPRESSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DEPRESSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANXIETY DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANXIETY DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANXIETY DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SCHIZOPHRENIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SCHIZOPHRENIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SCHIZOPHRENIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL EPILEPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL EPILEPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL EPILEPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OBESITY & WEIGHT MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OBESITY & WEIGHT MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OBESITY & WEIGHT MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CHRONIC RESPIRATORY DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHRONIC RESPIRATORY DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CHRONIC RESPIRATORY DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MENTAL & BEHAVIORAL HEALTH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MENTAL & BEHAVIORAL HEALTH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MENTAL & BEHAVIORAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MUSCULOSKELETAL DISORDERS / PAIN MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MUSCULOSKELETAL DISORDERS / PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MUSCULOSKELETAL DISORDERS / PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ONCOLOGY SUPPORT CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONCOLOGY SUPPORT CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ONCOLOGY SUPPORT CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GASTROINTESTINAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GASTROINTESTINAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GASTROINTESTINAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SMOKING CESSATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SMOKING CESSATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SMOKING CESSATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL WOMEN'S HEALTH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL WOMEN'S HEALTH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL WOMEN'S HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL REHABILITATION & PHYSICAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL REHABILITATION & PHYSICAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL REHABILITATION & PHYSICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SUBSTANCE USE DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SUBSTANCE USE DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SUBSTANCE USE DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SLEEP DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SLEEP DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SLEEP DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SMARTPHONE-BASED APPLICATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SMARTPHONE-BASED APPLICATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SMARTPHONE-BASED APPLICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL WEARABLE DEVICE-INTEGRATED DTX MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL WEARABLE DEVICE-INTEGRATED DTX MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL WEARABLE DEVICE-INTEGRATED DTX MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL AI/ML-BASED DIGITAL THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL AI/ML-BASED DIGITAL THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL AI/ML-BASED DIGITAL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VIRTUAL REALITY (VR)-BASED DTX MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VIRTUAL REALITY (VR)-BASED DTX MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VIRTUAL REALITY (VR)-BASED DTX MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DIGITAL MONITORING + FEEDBACK SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIGITAL MONITORING + FEEDBACK SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DIGITAL MONITORING + FEEDBACK SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL WEB-BASED / CROSS-PLATFORM THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL WEB-BASED / CROSS-PLATFORM THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL WEB-BASED / CROSS-PLATFORM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PATIENTS / DIRECT-TO-CONSUMER (D2C) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PATIENTS / DIRECT-TO-CONSUMER (D2C) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PATIENTS / DIRECT-TO-CONSUMER (D2C) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HEALTHCARE PROVIDERS (HOSPITALS & CLINICS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HEALTHCARE PROVIDERS (HOSPITALS & CLINICS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HEALTHCARE PROVIDERS (HOSPITALS & CLINICS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL EMPLOYERS / CORPORATE WELLNESS PROGRAMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL EMPLOYERS / CORPORATE WELLNESS PROGRAMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL EMPLOYERS / CORPORATE WELLNESS PROGRAMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PHARMACEUTICAL PARTNERSHIPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PHARMACEUTICAL PARTNERSHIPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PHARMACEUTICAL PARTNERSHIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GOVERNMENT & PUBLIC HEALTH SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GOVERNMENT & PUBLIC HEALTH SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GOVERNMENT & PUBLIC HEALTH SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HEALTHCARE PROVIDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HEALTHCARE PROVIDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HEALTHCARE PROVIDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL EMPLOYERS & CORPORATE WELLNESS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL EMPLOYERS & CORPORATE WELLNESS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL EMPLOYERS & CORPORATE WELLNESS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CAREGIVERS & REHABILITATION CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CAREGIVERS & REHABILITATION CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CAREGIVERS & REHABILITATION CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CLOUD-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CLOUD-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CLOUD-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ON-PREMISE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ON-PREMISE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ON-PREMISE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL HYBRID DEPLOYMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL HYBRID DEPLOYMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL HYBRID DEPLOYMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 183. GCC DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. GCC DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 186. GCC DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 187. GCC DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 188. GCC DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. GCC DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. GCC DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 207. G7 DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. G7 DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 210. G7 DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 211. G7 DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 212. G7 DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. G7 DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. G7 DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 215. NATO DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 216. NATO DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. NATO DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 218. NATO DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 219. NATO DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 220. NATO DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. NATO DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. NATO DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 232. CANADA DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. CANADA DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. CANADA DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 235. CANADA DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 236. CANADA DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 237. CANADA DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. CANADA DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. CANADA DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 240. MEXICO DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. MEXICO DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. MEXICO DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 243. MEXICO DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 244. MEXICO DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 245. MEXICO DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. MEXICO DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. MEXICO DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 248. BRAZIL DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 249. BRAZIL DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. BRAZIL DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 251. BRAZIL DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 252. BRAZIL DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 253. BRAZIL DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. BRAZIL DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. BRAZIL DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED KINGDOM DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED KINGDOM DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED KINGDOM DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED KINGDOM DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED KINGDOM DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED KINGDOM DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED KINGDOM DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED KINGDOM DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 264. GERMANY DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. GERMANY DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. GERMANY DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 267. GERMANY DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 268. GERMANY DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 269. GERMANY DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. GERMANY DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. GERMANY DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 272. FRANCE DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. FRANCE DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. FRANCE DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 275. FRANCE DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 276. FRANCE DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 277. FRANCE DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. FRANCE DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 279. FRANCE DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 280. RUSSIA DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. RUSSIA DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. RUSSIA DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 283. RUSSIA DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 284. RUSSIA DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 285. RUSSIA DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. RUSSIA DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. RUSSIA DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 288. ITALY DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 289. ITALY DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. ITALY DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 291. ITALY DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 292. ITALY DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 293. ITALY DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. ITALY DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. ITALY DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 296. SPAIN DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 297. SPAIN DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. SPAIN DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 299. SPAIN DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 300. SPAIN DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 301. SPAIN DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. SPAIN DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 303. SPAIN DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 312. INDIA DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 313. INDIA DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. INDIA DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 315. INDIA DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 316. INDIA DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 317. INDIA DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. INDIA DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 319. INDIA DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 320. JAPAN DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 321. JAPAN DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. JAPAN DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 323. JAPAN DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 324. JAPAN DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 325. JAPAN DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. JAPAN DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 327. JAPAN DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 328. AUSTRALIA DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 329. AUSTRALIA DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 330. AUSTRALIA DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 331. AUSTRALIA DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 332. AUSTRALIA DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 333. AUSTRALIA DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 334. AUSTRALIA DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 335. AUSTRALIA DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 336. SOUTH KOREA DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 337. SOUTH KOREA DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 338. SOUTH KOREA DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 339. SOUTH KOREA DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 340. SOUTH KOREA DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 341. SOUTH KOREA DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 342. SOUTH KOREA DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 343. SOUTH KOREA DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)